Related Experiment Video

Updated: Jun 20, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

PML: An emerging tumor suppressor and a target with therapeutic potential

Erin L Reineke1, Hung-Ying Kao

  • 1Department of Biochemistry, School of Medicine, Case Western Reserve University (CWRU) and the Comprehensive Cancer Center of CWRU. 10900 Euclid Avenue, Cleveland, Ohio 44106, USA.

Cancer Therapy
|September 17, 2009
PubMed

Insights

Promyelocytic leukemia protein (PML) acts as a tumor suppressor. Decreased PML expression in various cancers promotes oncogenesis by disrupting cell cycle control and apoptosis, necessitating therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Promyelocytic leukemia protein (PML) was initially identified as a tumor suppressor in Acute Promyelocytic Leukemia (APL).
  • Emerging evidence indicates reduced PML protein expression in diverse cancer types, though the underlying mechanisms remain unclear.
  • PML protein is crucial for maintaining cell cycle control and preventing apoptosis, acting as a key regulator in oncogenesis.

Purpose of the Study:

  • To investigate the broader role of promyelocytic leukemia protein (PML) as a tumor suppressor beyond Acute Promyelocytic Leukemia (APL).
  • To understand the mechanisms contributing to decreased PML expression in various cancers.
  • To explore therapeutic strategies targeting PML for cancer treatment.

Main Methods:

  • Review of recent studies on PML protein expression in different cancer types.
  • Analysis of the functional consequences of decreased PML expression on cell cycle and apoptosis.
  • Examination of the impact of PML nuclear bodies on cellular transcriptional profiles.
  • Evaluation of findings from mouse models investigating PML's role in oncogenesis.

Main Results:

  • Decreased expression of PML protein is observed in multiple cancer types.
  • Reduced PML levels correlate with loss of cell cycle control and impaired apoptosis.
  • Alterations in PML nuclear bodies affect the cell's transcriptional profile, promoting oncogenesis.
  • PML's contribution to cancer progression is confirmed in preclinical mouse studies.

Conclusions:

  • PML functions as a critical tumor suppressor in a variety of cancers.
  • Therapeutic strategies aimed at targeting PML warrant further development.
  • Understanding PML's role is essential for advancing cancer therapy.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...